ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,544.59
-0.78%
US Tech 100
19,240.80
-0.16%
Dow Jones
40,665.02
-1.29%
Brent Oil
84.08
-0.48%
Bitcoin
63,993.26
-0.14%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. BriaCell Therapeutics Corporation (BCTX) Quote

BriaCell Therapeutics Corporation

BriaCell Therapeutics Corporation (BCTX)

NASDAQ
0.76
-0.1611
(-17.49%)
At close: July 18 4:00PM
Delayed by 15 minutes
0.75
-0.01
( -1.32% )
After Hours: 6:12PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.75
Bid
0.74
Ask
0.75
Volume
12,868,487
0.72 Day's Range 0.9316
0.72 52 Week Range 7.59
Market Cap
16.934M
Previous Close
0.9211
Open
0.93
Last Trade
200
@
0.75
(formt)
Last Trade Time
18:19:20
Financial Volume
$ 10,162,736
VWAP
0.789738
Average Volume (3m)
141,771
Shares Outstanding
18,384,661
Dividend Yield
-
PE Ratio
-9.60
Earnings Per Share (EPS)
-1.1
Revenue
-
Net Profit
-20.3M

About BriaCell Therapeutics Corporation

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with I... BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies. Show more

Sector
Aircraft
Industry
Business Services, Nec
Website
www.briacell.com
Headquarters
Vancouver, British Columbia, Can
Founded
2009
BriaCell Therapeutics Corporation is listed in the Aircraft sector of the NASDAQ with ticker BCTX. The last closing price for BriaCell Therapeutics was $0.92. Over the last year, BriaCell Therapeutics shares have traded in a share price range of $ 0.72 to $ 7.59.

BriaCell Therapeutics currently has 18,384,661 shares outstanding. The market capitalization of BriaCell Therapeutics is $16.93 million. BriaCell Therapeutics has a price to earnings ratio (PE ratio) of -9.60.

BCTX Latest News

More News

Form 8-K - Current report

2 hours ago
Edgar (US Regulatory)

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3Significant reduction of “Eye-Bulging” metastatic breast...

11 hours ago
GlobeNewswire Inc.

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of...

June 03 2024
GlobeNewswire Inc.

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

May 30 2024
GlobeNewswire Inc.

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER...

May 28 2024
GlobeNewswire Inc.

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...

May 24 2024
GlobeNewswire Inc.

BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

May 17 2024
GlobeNewswire Inc.

BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...

May 15 2024
GlobeNewswire Inc.

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...

April 24 2024
GlobeNewswire Inc.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic...

April 10 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.26-25.74257425741.011.030.722014860.92114405CS
4-0.59-44.02985074631.341.390.721375591.01305252CS
12-1.42-65.43778801842.172.440.721417711.35550262CS
26-3.68-83.06997742664.434.610.721103672.11987438CS
52-5.9-88.72180451136.657.590.721043073.70055891CS
156-4.01-84.2436974794.7612.470.725353107.35016248CS
260-3.49-82.31132075474.2412.470.728416226.55785448CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 4.22
(60.46%)
2.68M
NVOSNovo Integrated Sciences Inc
$ 0.761
(26.35%)
6.9M
DRUGBright Minds Biosciences Inc
$ 1.27
(16.51%)
346.67k
SXTP60 Degrees Pharmaceuticals Inc
$ 0.28
(13.82%)
404.36k
TCTuanChe Ltd
$ 1.76
(13.55%)
41.04k
KITTNauticus Robotics Inc
$ 0.1015
(-21.26%)
9M
ZCMDZhongchao Inc
$ 1.12
(-15.79%)
358
SCHLScholastic Corporation
$ 32.16
(-12.04%)
9.45k
GDTCCytoMed Therapeutics Ltd
$ 2.06
(-10.05%)
4.13k
PLUGPlug Power Inc
$ 2.63
(-9.93%)
5.07M
KITTNauticus Robotics Inc
$ 0.1015
(-21.26%)
9M
NVOSNovo Integrated Sciences Inc
$ 0.761
(26.35%)
6.9M
NVDANVIDIA Corporation
$ 122.07
(0.81%)
5.89M
ONCOOnconetix Inc
$ 0.2031
(-6.96%)
5.65M
PLUGPlug Power Inc
$ 2.63
(-9.93%)
5.07M

BCTX Discussion

View Posts
Monksdream Monksdream 2 weeks ago
BCTX under $2
👍️0
Monksdream Monksdream 3 weeks ago
BCTX new 52 week low
👍️0
Monksdream Monksdream 3 weeks ago
BCTX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
BCTX. Under $3
👍️0
QuicKtip QuicKtip 3 months ago
$BCTX Shows “Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer”

Press Release: https://bit.ly/4aJmAoc

$BCTX #CancerTreatment #Innovation
👍️0
BigHeis BigHeis 4 months ago
Does anyone have information about the stock spinoff that occurred last year with this company? I have 600 shares of the spinoff security with 0 value and has remained that way since the spinoff. Thanks…
👍️0
Monksdream Monksdream 4 months ago
BCTX new 52 lo
👍️0
Monksdream Monksdream 4 months ago
BCTX new 52 lo
👍️0
Monksdream Monksdream 4 months ago
BCTX 10Q due March 13
👍️0
Monksdream Monksdream 5 months ago
BCTX new 52 week low
👍️0
Monksdream Monksdream 5 months ago
BCTX new 52 week low
👍️0
QuicKtip QuicKtip 8 months ago
$BCTX is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://finance.yahoo.com/news/briacell-records-responder-remarkable-improvement-120000404.html
👍️0
Sly1969 Sly1969 8 months ago
Good news today. I took a entry
👍️0
Monksdream Monksdream 9 months ago
BCTX new 52 week low
👍️0
benderostap4 benderostap4 1 year ago
2023 Anticipated Milestones, please?
👍️0
smallcapvoice smallcapvoice 1 year ago
$BCTX $15 Price Target

Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.

Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx

#Stocks #StocksToWatch #StockMarket
👍️0
smallcapvoice smallcapvoice 1 year ago
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch
👍️0
Onree Onree 1 year ago
Strange stock, but I've loved having it the past couple of years. I've mostly day traded, as there was a pretty good pattern last year, of early drops and late charges, and vice versa. I did end up getting stuck at around $10 so have been holding a lot at that level. Hopefully it runs again and I can keep chipping away at my mortgage because of the fancy researchers in Vancouver. Best of luck, all!
👍️0
chenzo11 chenzo11 2 years ago
Yep, I'm still here. She's getting ready to burst! Low float/high short interest, Fast track approval and now up on big volume. Gonna get interesting!
👍️0
Nickwvt Nickwvt 2 years ago
Under $4 by end of month
👍️0
crudeoil24 crudeoil24 2 years ago
BriaCell Therapeutics Price Target Announced at $25.00/Share by HC Wainwright & Co.
👍️0
crudeoil24 crudeoil24 2 years ago
BriaCell Reports Received FDA Fast Track Approval For Its Targeted Breast Cancer Immunotherapy

BCTX
👍️0
chenzo11 chenzo11 2 years ago
I'm still here....wait til you see what happens this week

We will dance!
👍️0
chenzo11 chenzo11 3 years ago
Closed above resistance of $10.50....We dance on Monday

Low float/high short interest. Setting up for big run
👍️0
lucky__stock lucky__stock 3 years ago
$BCTX BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

👍️0
lucky__stock lucky__stock 3 years ago
$BCTX announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.

Dr. Ostrand-Rosenberg has more than 40 years of experience leading investigations focused on the immune system’s response to cancer. She is currently the Robert & Jane Meyerhoff Professor of Biochemistry, Emeritus, and Professor of Biological Sciences, Emeritus, University of Maryland Baltimore County, Baltimore, MD, and has been working with the University since 1977. She was also appointed as the Adjunct Professor of Pathology, Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, in 2018. https://finance.yahoo.com/news/briacell-adds-pioneering-immunologist-cancer-130000276.html
👍️0
lucky__stock lucky__stock 3 years ago
$BCTX has added Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board!

Click here for a bio and to learn what she's bringing to the BriaCell team!

https://yhoo.it/3kbmmhX
👍️0
EyalCap EyalCap 3 years ago
Easy Money for more $ZOM shares $BCTX thanks to @MrZackMorris for the tip in his Reddit community.. called this out last month on my Instagram big profits.. shorts are still all over this.. squeeze is to be prepared for.. get in profit big and get out .. October is #BreastCancerAwarenessMonth also load on $ZOM ?? it acquired Pulse Vet

$BCTX thanks to @MrZackMorris for the tip in his Reddit community.. called this out last month on my Instagram big profits.. shorts are all over this now.. squeeze is to be prepared for.. get in profit big and get out .. October is #BreastCancerAwarenessMonth also load on $ZOM 💎 pic.twitter.com/wJVS4lZydq— BANLVL3 (@SellingStrikes) October 3, 2021
👍️0
StockHighAlert- StockHighAlert- 3 years ago
(Nasdaq: BCTX, BCTXW) (TSX-V: BCT) CEO highlights key achievements of the company including recent collaboration with ImaginAb https://yhoo.it/3CDPzc7
👍️0
StockHighAlert- StockHighAlert- 3 years ago
BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX-V:BCT) News Alert https://yhoo.it/3gmjQ6A #stocks #medical #stockstowatch

👍️0
Nebuchadnezzar Nebuchadnezzar 3 years ago
BCTX



https://schrts.co/gJajQPrD
👍️0
ThurstonHowell ThurstonHowell 3 years ago
MarketsandMarkets 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition: June 28-30, 2021
Dr. Williams will be speaking at the scientific conference at 11:30am ET on June 29, 2021.
The topic is “Personalized, off-the-shelf cellular immunotherapy for cancer”.
A copy of the presentation will be posted here: https://briacell.com/novel-technology/scientific-publications/.
For additional information on the conference and the speaker, please visit:
https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers

Separately, BriaCell has recently appointed Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC). Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis. More recently, Dr. Lopez-Lago has been interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies. Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

For additional information on BriaCell, please visit: https://briacell.com/.

👍️0
ThurstonHowell ThurstonHowell 3 years ago
https://www.globenewswire.com/en/news-release/2021/05/11/2226965/0/en/BriaCell-to-Participate-at-Upcoming-Conferences-and-Appoints-Senior-R-D-Director.html
👍️0
ThurstonHowell ThurstonHowell 3 years ago
https://www.globenewswire.com/news-release/2021/06/16/2248189/0/en/BriaCell-Therapeutics-Expands-Breast-Cancer-Platform-Technology-into-Prostate-Melanoma-and-Lung-Cancers.html
👍️0
ThurstonHowell ThurstonHowell 3 years ago
https://finance.yahoo.com/news/briacell-reports-12-0-months-111200861.html
👍️0
retireat40 retireat40 3 years ago
Terrible timing though. Absolutely killed any momentum.
👍️0
HabibiFresh HabibiFresh 3 years ago
Yeah that wasn't bad news with private offering 27m institutional investment bullish for me

Seems that market didn't panic cos of the word "offering"

However this trading really weird lol halt > drop > halt into 7 smash > > drop > halt down
👍️0
jwakstock jwakstock 3 years ago
Hopefully the squeeze alone will take it over $20.
👍️0
timetomakemoney timetomakemoney 3 years ago
Yes, Nasdaq halted it again, Those MMS who naked shorted thare stock are screwed
👍️0
cbrad10480 cbrad10480 3 years ago
My hunch the halt is because there are a bunch of FTD shares.
Thank You!

I like your hunch, let the squeeze begin!


cbrad
👍️0
timetomakemoney timetomakemoney 3 years ago
What the Hell, there was a market for 3 minutes then they halted it again.
👍️0
timetomakemoney timetomakemoney 3 years ago
PPS could go either way... My hunch the halt is because there are a bunch of FTD shares.
👍️0
cbrad10480 cbrad10480 3 years ago
I've never seen a halt for news and the news is a private placement.

Does that mean that once resumed, the pps will gravitate toward the offering price
or will it cause the pps to go up?

Sorry for the newbie question, just trying to understand a little better.

cbrad
👍️0
HabibiFresh HabibiFresh 3 years ago
We thinking buyout with this halt? Wouldn't halt this long for dilution
👍️0
HabibiFresh HabibiFresh 3 years ago
Yeah real curious was about to happen
👍️0
HabibiFresh HabibiFresh 3 years ago
100% resolution for eye-bulging tumors I love it
👍️0
timetomakemoney timetomakemoney 3 years ago
Over an hour and BCTX is still halted.
👍️0
HabibiFresh HabibiFresh 3 years ago
Yall seen a halt before big news before?
👍️0
Penny chatter Penny chatter 3 years ago
Has to be more than that as it's still halted
👍️0
retireat40 retireat40 3 years ago
Offering news out...$5.26 with exercise at $6.17 it appears.
👍️0
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved